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Objectives: Brentuximab vedotin is an orphan drug currently indicated for treat-
ment of patients with refractory/relapsed hodgkin lymphoma CD30+ following 
prior Auto Stem Cell Transplant (ASCT) or following two prior chemotherapy regi-
mens. This is a group of patients with a reported median survival of 12 months, 
with no defined standard of care and for whom clinical trials are single armed 
due to lack of appropriate comparators and scarcity of patients. Hence, an indirect 
comparison was performed to determine the cost-effectiveness of brentuximab 
vedotin in different countries. MethOds: A three state Markov model was devel-
oped. Effectiveness of brentuximab vedotin was obtained from the clinical trial of 
Gopal 2012. Effectiveness for the control group was obtained from 3 clinical trials 
evaluating survival of post-ASCT patients where data was disaggregated based on 
the patients´ response to prior ASCT/chemotherapy. The assumption was that only 
patients with ASCT/chemotherapy failure would serve as controls. The treatments 
received by the control group were based on the review of Martinez 2013, where 
64% received chemotherapy, 29% AlloSCT and 8% AutoSCT. Simulations were run for 
the Mexican and Venezuelan contexts. Direct medical costs were obtained from the 
local public sectors and WHO-CHOICE. Results: For the base case scenario of both 
countries the ICERs (USD/LYG) were respectively $38,614.34 (Mex) and $57,854.07 
(Ven), which compares favorably against accepted ICERs in the orphan drugs field. 
In the univariate sensitivity analysis the model was mainly sensitive to the costs 
of brentuximab, AutoSCT and AlloSCT. cOnclusiOns: Brentuximab vedotin is a 
cost-effective alternative for both countries, especially in the space of orphan drugs. 
The low costs of AutoSCT and AlloSCT in Venezuela relative to its GDP were what 
mainly accounted for higher ICERs. Differences in chemotherapy usage and costs 
did not alter the model. As a limitation, local epidemiology was not accounted for 
due to lack of data.
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Objectives: to perform cost-effectiveness analysis fulvestrant 500mg (F500) 
for the treatment of ﬁrst progression or recurrence of advanced breast cancer 
in postmenopausal patients compared with anastrozole 1mg (ANAS1), letrozole 
2.5mg (LET2,5), exemestane 25mg (EXE25) and exemestane 25mg+everolimus 
10mg (EXE25+EVE10). MethOds: the data on efficacy and safety of 2-line hor-
monal therapy of breast cancer were derived from a network meta-analysis and 
clinical data publication for overall survival (OS), progression free survival (PFS) 
and serious adverse events (SAE). We considered the direct costs on second and 
third line hormonal therapy and resource utilization. Data on resource usage, 
were based on expert opinion and open sources. 1-way sensitivity analyses were 
conducted. Results: in terms of OS F500 (mean 23.33 month) was as effective as 
ANAS1 (22.12) and more effective than LET2.5 (17.44) and EXE25 (18.31). The high-
est incremental cost-effectiveness ratio (ICER) estimated for F500 versus ANAS1 
was 84,592 USD per year with incremental effectiveness 1.21 month. The lowest 
ICER estimated for F500 versus LET2.5 was 22,873 USD per year with incremen-
tal effectiveness 5.90 month. The ICER for F500 versus EXE25 was 25,890 USD 
per year. In terms of PFS EXE25+EVE10 was more effective and costly, than F500. 
The CER for F500 was 1,714 USD per year versus 4,215 USD for EXE25+EVE10. 
A series of one-way sensitivity analyses showed this result is robust to variations 
in costs of drugs, physician examination, and variation in costs associated with 
SAE. cOnclusiOns: the use of F500 is more effective than LET2.5 and EXE25, and 
at least as efficacious as ANAS1 in terms of OS among postmenopausal women 
with advanced breast cancer after failure on 1-line endocrine therapy. In terms of 
PFS F500 less efficacious than EXE25+EVE10, however substantially cheaper. From 
perspective of federal health care system, the cost of LYG for F500 is less than the 
willingness to pay threshold.
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Objectives: Cancer accounts for around 1.3 million deaths and € 50 billion in 
health care expenditure in the European Union. Balancing increasing treatment 
costs and prevalence will be increasingly difficult for governments to manage. 
Advances in immunotherapies provide hope for a cancer cure; however its cost 
might be out of reach for governments under current health economic evalua-
tion methods which will be the aim of this research. MethOds: The years of 
life lost (YLL) in the UK due to cancer were obtained from the Institute of Health 
Metrics and Evaluation (IHME) database and multiplied by the NICE cost effec-
tiveness threshold of £20,000 per Quality Added life Year (QALY), this gave a first 
estimate of the potential cost of a cancer cure that would be within an 
acceptable cost effectiveness threshold. This cost was then modified to take into 
account the quality of life (QoL) of the general population, QALY discounting, 
cancer onset age, and other demographics. YLL due to disability in cancer were 
not included in the calculation. Results: It is estimated that 32.4% of the total 
YLL per year in the UK (5,615,310) are a consequence of cancer. The cost of sav-
ing these YYL at £20,000 per QALY was estimated to be around £12 billion for all 
cancers per year, meaning an extra £425 in taxes would have to be generated 
Objectives: Standard treatment for localized prostate cancer is radical prosta-
tectomy (PE) or radiation therapy (RT) which frequently cause erectile dysfunction 
(ED) and incontinence (IC). As tumor progression often is slow, active surveil-
lance (AS) has been proposed as an alternative treatment strategy. This study 
compares the cost-effectiveness of the three treatment strategies in a German 
context. MethOds: Based on claims data of a German sickness fund we ana-
lyzed men diagnosed with prostate cancer (ICD-10 code C61) in 2008. Life years 
gained and complication rates of ED and IC as well as costs of inpatient and 
outpatient treatment, pharmaceuticals, physical therapy, medical aids and co-
payments were tracked for 2.5 years after the initial treatment. An excess-cost 
analysis was applied. Strategies were compared in an age-matched and comor-
bidity-adjusted approach. Results: The baseline study sample included 25,376 
individuals. Exclusion of metastases, other cancer diagnoses and treatment strate-
gies resulted in 910 men with PE, 292 with RT and 124 with AS. After matching 
107 men remained in the AS group and 214 each in the PE and RT groups with 
a mean age of 70 years. Risk of long-term ED (PE: 0.112, RT: 0.009, AS: 0.056) 
and IC (PE: 0.313, RT: 0.009, AS: 0.084) was highest in the PE group. Compared to 
RT and AS, PE was associated with more life years gained during the cause of the 
study. Due to high inpatient costs of the initial surgery PE had ca. € 11,000 higher 
total per capita costs than RT and AS. cOnclusiOns: The analysis indicates that 
PE is associated with better prognosis and higher overall costs compared to RT 
and AS. 2.5 years follow-up might, however, not be enough to detect prostate 
cancer-specific deaths.
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Objectives: It is estimated that almost all cervical cancers are associated with 
HPV infection. In most industrialised countries, cervical screening and vaccina-
tion with a bivalent or quadrivalent vaccine are recommended to prevent the 
disease. The current study aimed to critically review the results of CEAs that have 
assessed the trade-off between screening and vaccination. MethOds: A system-
atic literature review was conducted in order to explore the cost-effectiveness 
of HPV vaccination strategies with or without different screening strategies 
within the geographical context of Western Europe, North America and Australia. 
Modelling approach, disease considered, vaccination/screening settings and 
costs were compared. Results: A total of 1,188 citations were identified and 
20 studies were included in the review. Heterogeneity was seen across studies 
in terms of modelling approach, disease and prevention strategies considered. 
Inclusion of more HPV-related diseases significantly improves cost-effectiveness. 
The strategies combining screening and vaccination were found to be cost-effec-
tive when compared to vaccination or screening alone. In terms of screening 
strategy, HPV DNA testing with cytological triage showed a trend to be the opti-
mal strategy in vaccinated girls. However the gain in benefits reduced as the 
interval between screenings is reduced. Delaying the starting age of screening 
could be cost saving, with a limited increase in risk of cancer. An increasing vac-
cine valence seemed to counterbalance the detrimental effect of delayed/less 
frequent screening while the total costs of cervical disease prevention/treatment 
may be maintained or decreased. Lastly, vaccine price seemed to affect the incre-
mental cost-effectiveness ratio proportionally. cOnclusiOns: Despite hetero-
geneity in methodology across studies, similar trend of cost-effectiveness of 
competing prevention strategies was witnessed. In light of the trial results of the 
new nonavalent HPV vaccine, which provides protection against five additional 
types of the virus, the optimal prevention strategy needs to be reassessed within 
local context.
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Objectives: To conduct a pharmacoeconomic evaluation of the application of ful-
vestrant compared with docetaxel and paclitaxel in the treatment of metastatic 
breast cancer in second-line chemotherapy. MethOds: Literature review of clinical 
effectiveness and safety of use of fulvestrant was conducted. Assess of the quality 
of research and level of evidence obtained in these results was performed. Direct 
medical costs consisted of the cost of the drug, the cost of patient management and 
correction of side effects. Duration of therapy, its effectiveness and side effects were 
obtained from relevant studies on clinical effectiveness (CONFIRM 2013, S. Jones et 
al. 2005). The cost of certain hematologic side effects have been taken from the study 
Belousov DU et al, 2012. To estimate the duration of hospital stay in the development 
of not hematological side effects, conducted a survey of experts. After calculating 
the total medical costs on compared regimens was conducted cost - effectiveness 
analysis with the calculation of CER. ResultsAccording to studies CONFIRM, 2013 
and S. Jones et al. 2005., in patients taking fulvestrant PFS and OS were to 6.5 and 
26.4 months, docetaxel - 5,7 and 15.4 months, paclitaxel - 3,6 and 12.7 months. The 
total cost of treatment were maximal for the docetaxel - 17685 USD, significantly 
lower for fulvestrant - 11803 USD and the minimal for paclitaxel - 7205 USD Cost-
effectiveness analysis showed that in spite of the average cost of treatment, taking 
into account its effectiveness in PFS and OS, the best CER was shown for fulves-
trant, followed by paclitaxel and docetaxel. The sensitivity analysis showed that 
the simulation results are resistant to increase of the prices for fulvestrant i up to 
12%. cOnclusiOns: The use of fulvestrant for the treatment of metastatic breast 
cancer in second-line chemotherapy is more cost effective than the appointment 
of docetaxel and paclitaxel.
